U.S. pharma large copyright scrapped two experimental weight loss products last calendar year—a as soon as-daily pill, lotiglipron, resulting from elevated liver enzymes and a twice-daily pill, danuglipron, resulting from strong Uncomfortable side effects—but CEO Albert Bourla has reported the company is decided to “Perform and acquire” ins